Delhi health minister Pankaj Kumar Singh claimed on Friday that there is no shortage of essential medicines in state govt-run ...

The former pub landlady from Grenoside, Sheffield, was told she had two to four years to live when she was diagnosed with a ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Gossamer Bio, Inc. , a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and ...

Long-term use of melatonin supplements for sleep may be linked to a greater risk for heart failure, a recent study suggests.

Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

Rocket Doctor AI Inc. ("Rocket Doctor AI") announces that it has granted an aggregate 831,356 restricted share units ("RSUs") and 20,964 stock options ("Options") to consultants and employees of the ...

A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...

Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review ...

Dozens of Scotland’s healthcare workers have been recognised in a glittering annual awards ceremony celebrating the nation’s ...